Vita Life Sciences Ltd
ASX:VLS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.6
2.46
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Vita Life Sciences Ltd
Vita Life Sciences Ltd
Net Issuance of Common Stock
Vita Life Sciences Ltd
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Net Issuance of Common Stock
-AU$178k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-56%
|
CAGR 10-Years
-7%
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Net Issuance of Common Stock
-AU$10.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Net Issuance of Common Stock
AU$4.2m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-17%
|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Net Issuance of Common Stock
AU$100.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
179%
|
CAGR 10-Years
39%
|
|
|
Probiotec Ltd
ASX:PBP
|
Net Issuance of Common Stock
AU$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Arovella Therapeutics Ltd
ASX:ALA
|
Net Issuance of Common Stock
AU$14.6m
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
Vita Life Sciences Ltd
Glance View
Vita Life Sciences Ltd. engages in the formulation, packaging, sale and distribution of vitamins and supplements. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-08-23. The firm is involved in the formulating, packaging, sales and distributing vitamins and supplements. The Company’s core business is the development and distribution of over the counter (OTC) medicines, as well as complementary and alternative medicines, dietary supplements and health foods under various brand names throughout Australia, Malaysia, Singapore, Thailand, Vietnam, China and Indonesia. The company offers products under the brands, such as Herbs of Gold, VitaHealth, VitaScience and VitaLife. The firm operates in Australia, Singapore, Malaysia and others. The firm subsidiaries include Tetley Research Pty Limited, Tetley Treadmills Pty Limited, Tetley Manufacturing Pty Limited, Vimed Bio Sciences Pty Limited, Allrad No 19 Pty Limited, Lovin Pharma International Limited, Herbs of Gold Pty Limited, VitaHealth Laboratories Australia Pty Limited and Vita Institute of Health Pty Ltd.
See Also
What is Vita Life Sciences Ltd's Net Issuance of Common Stock?
Net Issuance of Common Stock
-178k
AUD
Based on the financial report for Jun 30, 2024, Vita Life Sciences Ltd's Net Issuance of Common Stock amounts to -178k AUD.
What is Vita Life Sciences Ltd's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 10Y
-7%
Over the last year, the Net Issuance of Common Stock growth was 48%.
You don't have any saved screeners yet
